3 minute read
Bioengineering AG
Name ›
Address/P.O. Box ›
Postal Code/City › Country › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›
Areas of Activity ›
Biological Patents ›
Request for ›
Further Collaborations BioCopy AG
c/o Switzerland Innovation Park Basel Area AG Gewerbestrasse 24 4123 Allschwil Switzerland Dr Günter Roth +49-174-78-67-919 guenter.roth@biocopy.de www.biocpy.ch
IL
26 2016 Biochemistry
l Biomolecular interaction studies l High-throughput kinetics l Vaccine development l Immuno-oncology
Predominantly granted patent portfolio with currently 16 patent families that broadly secure our innovative technology and its applications worldwide
We are interested in collaborations with companies in the field of vaccine development and T-cell therapies.
BioCopy has developed a globally unique method to copy biomolecules. This patented method is broadly applicable and enables rapid development of both, Bcell and T-cell immunotherapies and diagnostics. The target molecules can derive from a pathogen (for vaccines) or from a tumor (for cancer therapies). BioCopy is thus one of few companies worldwide that addresses two booming billion-dollar markets with its innovative technology platform: ultra-fast target identification for vaccines in the field of infectious diseases and T-cell therapy screenings in the field of oncology.
Copying Technology
The basis of the BioCopy innovation is a biomolecule copier, which, in analogy to a photocopier, copies DNA, RNA or proteins from a DNA matrix. The genetic information, e.g. of a pathogen, is transferred to a special cavity chip so that each cavity contains a different fragment or mutation of the pathogen genome. Each cavity corresponds to an individual reaction chamber during the copying process. After adding a transcription/translation mixture and sealing the cavity chip with a specially coated glass slide, an individual copy of the contained fragment or mutation is generated in each cavity (“pixel”/ spot) as DNA, RNA or protein. This copy product binds to the slide surface, creating a corresponding array. The resulting microarrays consist of thousands of spots which can be analyzed simultaneously with BioCopy’s SCORE-detection system.
Detection Technology
Single color reflectometry (SCORE) enables label-free, real-time, high-throughput screening by analysis of biomolecular interactions and reliable determination of kinetic binding parameters. The SCORE system detects these interactions by measuring the change in layer thickness on the array surface that causes a color change. The SCORE system converts this color change into a binding signal. The graph can then be visualized immediately as an image or video.
Custom microarrays with over 1,000 different DNA, RNA or protein species on the surface can be analyzed within an hour using less than 10 μg of the target molecule. Compared to state-of-the-art, this innovative technology enables measurements with a sample throughput that is 100 fold higher and a sample and material consumption that is 10 fold lower.
Development of innovative Vaccines and Immune Therapeutics
Vaccinations are the best way to curtail epidemics. Pathogens change their structure frequently and rapidly. Current methods of vaccine development can not keep up with these high mutation rates. With BioCopy’s technology, molecular changes in new or mutated pathogens can be identified within days, so that adapted, optimized vaccine precursors can be rapidly provided to protect against future pandemics. BioCopy’s technology can identifiy vaccine precursors for classical antibody-inducing B-cell vaccines as well as precursor identification of specific T-cell vaccines. Such a T-cell vaccine becomes vital when either the pathogen does not present good B-cell epitopes, or a classic B-cell response vaccine could cause dangerous side effects.
T-cell response characterization is also needed in the field of immuno-oncology, where T-cells are used to specifically eliminate tumor cells. BioCopy’s ultrahigh-throughput approach significantly accelerates the identification or development of selective, highly specific candidates for cancer therapeutics (e.g. for T-cell based cancer therapies) and facilitates extensive preclinical safety screening.
